fingolimod hydrochloride has been researched along with c-peptide in 1 studies
| Studies (fingolimod hydrochloride) | Trials (fingolimod hydrochloride) | Recent Studies (post-2010) (fingolimod hydrochloride) | Studies (c-peptide) | Trials (c-peptide) | Recent Studies (post-2010) (c-peptide) |
|---|---|---|---|---|---|
| 2,771 | 157 | 2,062 | 9,053 | 1,632 | 2,445 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, CC; Emamaullee, JA; James Shapiro, AM; Merani, S; Truong, W | 1 |
1 other study(ies) available for fingolimod hydrochloride and c-peptide
| Article | Year |
|---|---|
Human islet function is not impaired by the sphingosine-1-phosphate receptor modulator FTY720.
Topics: Animals; Apoptosis; Blood Glucose; C-Peptide; Cells, Cultured; Fingolimod Hydrochloride; Follow-Up Studies; Glucose Tolerance Test; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; In Situ Nick-End Labeling; Insulin; Insulin Secretion; Islets of Langerhans; Islets of Langerhans Transplantation; Mice; Mice, Inbred C57BL; Propylene Glycols; Receptors, Lysosphingolipid; Sphingosine; Tissue and Organ Procurement | 2007 |